June 28th 2025
The FDA removed REMS and reduced certain monitoring needs for liso-cel and ide-cel in B-cell malignancies.
AE Profile of Bispecific Antibodies Can Be Predictable in Myeloma Management
September 13th 2024Both community and academic nurses must know what to expect and how to react to adverse events from bispecific antibody treatment in myeloma; however, Donna Catamero, ANP-BC, OCN, CCRC, notes this can be predictable for providers.